Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA] clinical trials

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

This study looks at new ways to treat a type of breast cancer called triple-negative early breast cancer. It compares a new drug combination with standard treatment to see if it works better at shrinking tumours before surgery and stopping cancer from coming back.